Adenosine A2A receptor activation reduces brain metastasis via SDF-1/CXCR4 axis and protecting blood-brain barrier

Mol Carcinog. 2020 Apr;59(4):390-398. doi: 10.1002/mc.23161. Epub 2020 Feb 9.

Abstract

Brain metastasis is a leading cause of death worldwide, but the mechanism involved remains unclear. Stromal cell-derived factor-1 (SDF-1)/C-X-C motif chemokine receptor 4 (CXCR4) signaling has been reported to induce the directed metastasis of cancers, and adenosine A2A receptor activation suppresses the SDF-1/CXCR4 interaction. However, whether A2A receptor activation implicates the SDF-1/CXCR4 signaling pathway and thus modulates brain metastasis remains unclear. In this study, Western blot was performed to evaluate the protein levels. Cell invasion and migration assays were used to estimate the metastasis ability of PC-9 cells. The viability of cells was demonstrated by lactate dehydrogenase and cell proliferation assays. And the findings in vitro were further identified in nude mice. Notably, adenosine A2A receptor activation inhibited the proliferation and viability of PC-9 cells and thus suppressed the brain metastasis. A2A receptor stimulation protected the function of blood-brain barrier (BBB). The suppression of brain metastasis and the protection of BBB by A2A receptor relied on SDF-1/CXCR4 signaling, and treatment using A2A receptor agonist and CXCR4 antagonist protected the nude mice from malignancy metastasis in vivo. Adenosine A2A receptor activation suppressed the brain metastasis by implicating the SDF-1/CXCR4 axis and protecting the BBB.

Keywords: C-X-C motif chemokine receptor 4 (CXCR4); adenosine A2A receptor; metastasis; stromal cell-derived factor-1 (SDF-1).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / analogs & derivatives
  • Adenosine / pharmacology
  • Adenosine A2 Receptor Agonists / pharmacology*
  • Animals
  • Benzylamines
  • Blood-Brain Barrier / drug effects*
  • Blood-Brain Barrier / metabolism
  • Brain Neoplasms / prevention & control*
  • Brain Neoplasms / secondary
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Chemokine CXCL12 / metabolism*
  • Cyclams
  • Heterocyclic Compounds / pharmacology
  • Humans
  • Lung Neoplasms / pathology
  • Lung Neoplasms / prevention & control*
  • Mice, Inbred BALB C
  • Mice, Nude
  • Phenethylamines / pharmacology
  • Receptor, Adenosine A2A / metabolism*
  • Receptors, CXCR4 / antagonists & inhibitors*
  • Receptors, CXCR4 / metabolism
  • Xenograft Model Antitumor Assays / methods

Substances

  • Adenosine A2 Receptor Agonists
  • Benzylamines
  • CXCL12 protein, human
  • CXCR4 protein, human
  • Chemokine CXCL12
  • Cyclams
  • Heterocyclic Compounds
  • Phenethylamines
  • Receptor, Adenosine A2A
  • Receptors, CXCR4
  • 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
  • Adenosine
  • plerixafor